ImmunID Continues to Strengthen its Scientific and Medical Advisory Board with Dr Miguel-Angel Perales

July 8, 2014

GRENOBLE, France, July 8, 2014 /PRNewswire/ — ImmunID announced today that Dr Miguel Perales, Deputy Chief, Adult Bone Marrow Transplant Service and Director, Adult Stem Cell Transplant Fellowship at Memorial Sloan Kettering Cancer Center in New York, is joining its Scientific Advisory Board.


Dr Perales’ clinical practice focuses on allogeneic and autologous stem cell transplantation for hematological malignancies as well as novel immune-based strategies for the treatment of cancer in general. His research interests include translational research in stem cell transplantation, tumor immunology, and the development of cytokine and cellular therapies for cancer. Dr. Perales has experience in hematologic malignancies, bone marrow transplantation, immune reconstitution, tumor immunology, and vaccine development.

“We are thrilled to have Dr. Perales join our Board, complementing the skills of our team and extending our international reach,” said Bernhard Sixt, Chairman and CEO of ImmunID. “Dr Perales is a talented and respected medical oncologist, and a pioneer in cancer immunotherapy,” he added.

“Dr Perales’ experience in cancer therapy and his patient-oriented approach will be very helpful to ImmunID in the development of clinically useful new immune molecular diagnostics and in the optimization of our medical strategy,” commented Nicolas Pasqual, Chief Scientific Officer and co-founder of ImmunID.

Miguel Perales said: “I am excited to support ImmunID in the clinical development of its immune molecular diagnostics tests, which provide unprecedented information on the patient immunocompetence and strongly augment our understanding of patient response to therapy.” ImmunID’s immunocompetence tests have a real and solid potential to change routine clinical practice in the near future”.

Follow Dr Miguel Perales on Twitter: @DrMiguelPerales

About ImmunID

ImmunID has been a pioneer in the immune molecular diagnostic field since 2005. Its two clinical products ImmunTraCkeR® and ImmunIg® evaluate T and B cell repertoire diversity, respectively. The company is establishing ImmunTraCkeR® as the general immune companion diagnostic for all immunotherapies and setting the general immune molecular diagnostics standard globally. ImmunID collaborates with leading clinical research centers and biopharmaceutical companies worldwide to further validate ImmunTraCkeR® as an immune companion diagnostic test for new immunotherapies and to widen clinical utility of its products. The company is ISO9001 certified and runs an ISO13485 accredited production and R&D facility in the MINATEC high-tech campus in Grenoble, France. In addition, ImmunID has applied for CAP accreditation / CLIA certification of its central lab to be able to provide ImmunTraCkeR® routinely to clinical patients in the United States.

www.immunid.com – Follow ImmunID on Twitter: @ImmunID

For further information, please contact ImmunID:
Bernhard Sixt
Chairman and CEO
Phone: +33 438 785 770

Logo – http://photos.prnewswire.com/prnh/20140707/124850


Source: PR Newswire

comments powered by Disqus